IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sui-Po Zhang Confirmation No.: 7714

Serial No.: 09/870,338 Art Unit: 1636

Filed: May 30, 2001 Examiner: Nancy-T. Vogel

For : Neuroblastoma Cell Lines Expressing the Alpha2delta Subunit of Calcium Channels and

Methods Therefor

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May 17, 2005
(Date of Deposit)

Laura A. Donnelly
(Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/
(Signature)

May 17, 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on May 30, 2003, and January 24, 2002.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the

35/20/2005 HVUONG1 00000017 100750 09870

10 CC-1806

information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

in accordance with §1.97(b), since this information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

☐ In accordance with §1.97(c), this Information

Disclosure Statement is being filed after the period set forth

in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or

an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ORT- \boxtimes 1440/LAD for the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the X attached Form PTO-1449 are enclosed herewith. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). 冈 There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1440/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/
Laura A. Donnelly
Reg. No. 38,435
Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: May 17, 2005 Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1440/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/
Laura A. Donnelly
Reg. No. 38,435
Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: May 17, 2005 Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1440/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/
Laura A. Donnelly
Reg. No. 38,435
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729
DATED: May 17, 2005

MAY 1 9 2005 BMISS

MISSION UNDER MPEP 609 D

Page 1 of 1

Confirmation Number	7714	
Application Number	09/870,338	
Filing Date	05/30/2001	
First Named Inventor	Sui-Po Zhang	
Group Art Unit	1636	
Examiner Name	Nancy T. Vogel	
Attorney Docket Number	ORT-1440	

U.S. PATENT DOCUMENTS					
	U.S. Patent Doc		ment		
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Kind Code ² Number (if known)		Pages, Columns, Lines, where relevant passages or relevant figures appear
		, , , , , , , , , , , , , , , , , , ,			
					·
				-	
					,

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures Name of Patentee or Examiner Initials Cite Applicant of Cited Document KindCode⁵ Office³ Number⁴ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T^2 Cite No.1 title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Examiner Initials* European Search Report dated July 22, 2004, for corresponding EP application 02737215.0.

Examiner	Date		
Signature	 Considered	 	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0661-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co

estitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

to respond to a conduction of union leader unless it displays a valid Only Conduct limited.			
Confirmation Number	7714		
Application Number	09/870,338		
Filing Date	05/30/2001		
First Named Inventor	Sui-Po Zhang		
Group Art Unit	1636		
Examiner Name	Nancy T. Vogel		
Attorney Docket Number	ORT-1440		

U.S. PATENT DOCUMENTS U.S. Patent Document **Date of Publication** Pages, Columns, Lines, Name of Patentee or Applicant Cite Kind Code of Cited Document where relevant passages or of Cited Document Initials Number (if known) relevant figures appear No. mm-dd-yyyy

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Pages, Columns, Lines, where relevant Publication of Name of Patentee or Cited Document passages or relevant Exam Applicant of Cited Document Initials figures appear Office³ Number⁴ KindCode⁵ mm-dd-yyyy No 1 WO Α 96/39512 Warner Lambert Co. 12-12-1996

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Cite Exam journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials No. TARRONI ET AL, "Anti-beta-2 subunit antisense oligonucleotides modulate the surface expression of the alph-1 subunit of N-type omega-CTX sesitive Ca-2+ channels in IMR 32 human neuroblastoma cells", Biochemical and Biophysical Research Communications, Vol. 201, No. 1 (1994) pp 180-185. WYATT ET AL, "The effect overexpression of auxillary Ca2+ channel subunits on native Ca2 channel currents in undifferentiated mammalian NG108-15 cells". Journal of Physiology, Vol. 510, No. 2 (July 15, 1998) pp 347-360. BROWN ET AL, "Isolation of the (3H)gabapentin-binding protein/alpha2delta Ca2+ channel subunit from porcine brain: Development of a radioligand binding assay for alpha2delta subunits using (3H) leucine", Analytical Biochemistry, Vol. 255, No. 2 (January 15, 1998) pp. 236-243.

Examiner	<u> </u>	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.